Improving drug delivery for heart disease treatment
Official title: Targeted drug delivery for the treatment of cardiovascular disease and its clinical complications
Funded at Wake Forest University Health Sciences · NIH-11010388 · Data updated 2026-11-12
This study is exploring a new way to deliver heart disease treatments directly to the areas that need them most, using tiny particles that can help the medicine work better for people with conditions like atherosclerosis and thrombosis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | January 15, 2024 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $249,000 |
| NIH project number | 5R00HL157690-04 |
| Project ID | NIH-11010388 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with atherosclerosis or venous thrombosis.
✕Less likely to help
Patients with non-cardiovascular diseases or those without significant atherosclerotic or thrombotic conditions may not benefit from this research.
What this research studies
This research focuses on enhancing the delivery of therapies specifically to areas affected by cardiovascular diseases, such as atherosclerosis and thrombosis. The approach involves using advanced nanoparticle technologies to create targeted drug delivery systems that can improve the accumulation of treatments at the sites of disease. By utilizing cell-mediated delivery methods, the researchers aim to ensure that these nanoparticles effectively reach and treat the problematic areas in the blood vessels. This innovative strategy could lead to more effective treatments for patients suffering from heart-related conditions.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cardiovascular diseases, potentially reducing the risk of heart attacks and strokes.
How similar studies have gone: Previous research has shown promise in using targeted drug delivery systems for other conditions, indicating potential success for this novel approach in cardiovascular disease.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Maiocchi, Sophie — Wake Forest University Health Sciences
- Study coordinator: Maiocchi, Sophie
Related research
Other NIH-funded projects on the same topics.
-
Understanding how genetic changes in blood cells relate to heart disease in people with HIV
A study will look at how age-related blood cell mutations and large chromosomal changes might contribute to heart disease risk in people living with HIV.
-
Food allergy antibodies linked to heart disease risk in adults
Many adults have antibodies to foods without symptoms, and this study asks whether those antibodies are linked to higher risk of heart disease and related conditions.
-
Mindfulness training to lower cardiovascular risk for moms and babies during pregnancy
A mindfulness program is being tested during pregnancy to help prevent high blood pressure and heart problems for mothers and their babies.
-
Integrating clinical pharmacists into HIV care to reduce cardiovascular disease in people with HIV
A pharmacist-led program in HIV care aims to prevent and manage heart disease risks like high blood pressure, diabetes, and high cholesterol in people living with HIV.
-
Integrating heart care into HIV services in Botswana using statins
This project tests a simple, scalable approach to help people with HIV in Botswana start and stay on statin therapy to prevent heart attacks and strokes.
-
A heart-healthy program for aging HIV patients using therapy pets to help blood pressure
A study tests whether using the human-animal bond from dog ownership can help older adults living with HIV control their blood pressure and improve heart health.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.